CTOR
Price:
$0.664
Market Cap:
$61.74M
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Industry
Drug Manufacturers - General
IPO Date
2022-12-08
Stock Exchange
NASDAQ
Ticker
CTOR
According to Citius Oncology, Inc.’s latest financial reports and current stock price. The company's current ROE is -99.47%. This represents a change of 253.25% compared to the average of -28.16% of the last 4 quarters.
The mean historical ROE of Citius Oncology, Inc. over the last ten years is -45.18%. The current -99.47% ROE has changed 120.18% with respect to the historical average. Over the past ten years (40 quarters), CTOR's ROE was at its highest in in the June 2022 quarter at 0%. The ROE was at its lowest in in the March 2026 quarter at -75.45%.
Average
-45.18%
Median
-47.78%
Minimum
-55.19%
Maximum
-29.96%
Discovering the peaks and valleys of Citius Oncology, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 65.97%
Maximum Annual ROE = -29.96%
Minimum Annual Increase = -7.82%
Minimum Annual ROE = -55.19%
| Year | ROE | Change |
|---|---|---|
| 2025 | -55.19% | 20.41% |
| 2024 | -45.84% | -7.82% |
| 2023 | -49.72% | 65.97% |
The current ROE of Citius Oncology, Inc. (CTOR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-50.25%
5-year avg
-45.18%
10-year avg
-45.18%
Citius Oncology, Inc.’s ROE is less than Scilex Holding Company (190.13%), greater than Actuate Therapeutics Inc (-430.93%), greater than Forte Biosciences, Inc. (-106.16%), less than Spero Therapeutics, Inc. (35.58%), greater than Applied Therapeutics, Inc. (-65.63%), less than Vor Biopharma Inc. (87.31%), greater than Seres Therapeutics, Inc. (-127.30%), greater than Fate Therapeutics, Inc. (-58.89%), greater than LENSAR, Inc. (-514.92%), less than Owlet, Inc. (1.14%),
| Company | ROE | Market cap |
|---|---|---|
| 190.13% | $72.18M | |
| -430.93% | $48.33M | |
| -106.16% | $243.83M | |
| 35.58% | $165.02M | |
| -65.63% | $14.86M | |
| 87.31% | $98.42M | |
| -127.30% | $55.20M | |
| -58.89% | $240.11M | |
| -514.92% | $70.45M | |
| 1.14% | $84.14M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Citius Oncology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Citius Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Citius Oncology, Inc.'s ROE?
How is the ROE calculated for Citius Oncology, Inc. (CTOR)?
What is the highest ROE for Citius Oncology, Inc. (CTOR)?
What is the 3-year average ROE for Citius Oncology, Inc. (CTOR)?
What is the 5-year average ROE for Citius Oncology, Inc. (CTOR)?
How does the current ROE for Citius Oncology, Inc. (CTOR) compare to its historical average?